Pfizer Beats Estimates Even as Biggest Product Falls Short

  • Prevnar vaccine falls short as Ibrance, Xeljanz top estimates
  • ‘Pfizer remains a company in flux,’ says analyst Anderson

Pfizer's Earnings Beat Dampened by Prevnar Shortfall

Pfizer Inc.’s biggest product, the vaccine Prevnar, fell short of sales estimates in the second quarter, though the drugmaker posted earnings that beat analysts’ estimates thanks to strong sales of two of its newest drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.